CMS selecciona 10 medicamentos para negociación de precios –

by tiempoantenacom

Medicare Drug Pricing Negotiations: A Step Towards Affordable Medications


In a recent development, ⁤the Centers for ⁤Medicare ​& ‍Medicaid Services (CMS) has released a fact sheet outlining its Medicare Drug Price Negotiation Program. This program​ aims to address the rising costs ⁣of prescription drugs and make medications more affordable for Medicare beneficiaries.⁤ The program has garnered attention and has been ‌covered ⁤by reputable news sources‌ such as The New York Times.

The CMS‌ Fact Sheet

The CMS fact sheet provides detailed information ⁣about the program and its⁤ objectives. It‍ highlights the‌ importance of negotiating drug prices to ensure that Medicare beneficiaries have access to affordable medications. The ​fact sheet⁢ also⁣ lists⁢ the companies that ⁣manufacture the⁣ drugs included⁢ in the program.

Medications⁢ Included in ⁣the Program

The following⁢ medications are included in the​ Medicare Drug Price Negotiation Program:

  1. Eliquis – Manufactured​ by Bristol Myers Squibb and Pfizer
  2. Jardiance ⁢ – Manufactured ‌by Boehringer Ingelheim and ‍Eli Lilly
  3. Xarelto – Manufactured by Johnson & Johnson
  4. Januvia ⁢ – Manufactured by Merck
  5. Relleno ​ –​ Manufactured by AstraZeneca
  6. Entresto – ⁣Manufactured by ⁤Novartis
  7. Enbrel –‌ Manufactured by Amgen
  8. Imbruvica – Manufactured by AbbVie and Johnson & Johnson
  9. Estelar – Manufactured by Johnson & Johnson
  10. Fiasp and NovoLog – Manufactured by ‌Novo Nordisk

This program is a significant ⁣step towards addressing the issue​ of high drug⁣ prices and ​ensuring⁤ that Medicare beneficiaries can access the medications⁢ they need ⁣without financial burden. By⁣ negotiating drug​ prices, CMS aims ‌to create a more affordable healthcare system for all.


The⁣ Medicare Drug ​Price Negotiation Program is a promising initiative that aims to make prescription drugs more affordable for Medicare beneficiaries. With the inclusion of various medications from different manufacturers, this program has the potential to bring about positive change in the healthcare ⁣industry. It is a ⁢step towards ⁣ensuring that individuals can ⁣access the⁤ medications they need without facing​ exorbitant costs.

Sources: CMS Fact​ Sheet, The New York⁢ Times

You may also like

Leave a Comment